Hypothesis

We hypothesize that a federated learning framework incorporating causal graph regularization into multimodal transformer architectures will improve detection of rare, clinically actionable molecular subtypes compared with standard sequential or parallel multi‑omics integration.

Mechanistic Rationale

Recent multi‑omics integration shows clinical value by combining genomics, transcriptomics, proteomics, metabolomics, and epigenomics, achieving AUCs of 0.81‑0.87 for early‑detection tasks [1]. However, current approaches either concatenate data sequentially or fuse them in parallel, which can obscure causal relationships between molecular layers and limit generalizability across diverse populations [2], 3], 4].

We propose that embedding a causal prior—derived from known regulatory networks (e.g., transcription factor → target gene, enzyme → metabolite)—into the attention mechanism of a transformer forces the model to weigh features according to their putative causal influence. This causal regularization encourages the network to learn representations that reflect upstream drivers rather than mere correlations, thereby enhancing the signal of rare subtypes that are driven by specific upstream alterations.

Federated learning addresses privacy and data heterogeneity by training the model across multiple institutions without sharing raw data, improving external validity [1]. By combining federated averaging with causal graph regularization, we expect the model to capture shared causal patterns while preserving site‑specific noise structures.

Testable Predictions

1. Performance gain: In a held‑out test set of colorectal cancer patients, the federated causal transformer will achieve an AUC ≥0.90 for identifying the hypermutated, immunogenic subtype described in [2], surpassing the best reported AUC of 0.87 from sequential integration.
2. Calibration improvement: Predicted probabilities will show better calibration (lower Brier score) than both sequential and parallel fusion baselines, indicating more reliable risk estimates.
3. Feature attribution consistency: Causal attention weights will align with known driver alterations (e.g., KRAS mutation, MSI status) more often than attention weights from non‑causal transformers, as measured by rank‑correlation with curated driver lists.
4. Cross‑site robustness: When trained on data from three geographically distinct cohorts and tested on a fourth unseen cohort, the federated causal model will retain ≥80% of its AUC, whereas non‑federated baselines will drop >15% due to batch effects.

Experimental Design

• Data: Multi‑omics datasets (whole‑genome sequencing, RNA‑seq, proteomics, metabolomics, DNA methylation) from four independent colorectal cancer cohorts (total n≈1200).
• Models: (a) Federated causal transformer (our proposal), (b) Federated sequential transformer, (c) Federated parallel transformer, (d) Centralized non‑federated causal transformer (upper bound).
• Training: Each site trains locally for 5 epochs; server aggregates weights via federated averaging. Causal regularization strength λ is tuned via internal cross‑validation.
• Evaluation: Stratified 5‑fold cross‑validation within each site; final assessment on the held‑out fourth site. Metrics: AUC, Brier score, calibration plot, attention‑driver rank correlation.
• Statistical test: DeLong’s test for AUC comparison; paired t‑test for Brier scores; permutation test for attribution consistency.

Falsifiability

If the federated causal transformer fails to outperform the best baseline by a statistically significant margin (p>0.05) on any of the primary metrics (AUC, Brier score, attribution consistency), the hypothesis is falsified. Likewise, if causal attention weights show no greater alignment with known drivers than random weighting, the proposed mechanistic link between causal regularization and subtype detection is refuted.

Potential Impact

Confirming this hypothesis would provide a practical pathway to privacy‑preserving, biologically interpretable multi‑omics models that excel at discovering rare disease subtypes, directly informing patient‑specific therapy selection and accelerating the shift toward proactive, individualized care.